You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions
Chicago, where thousands in the cancer world gather each year.Adam Feuerstein/STAT
By Adam Feuerstein, Matthew Herper, and Angus Chen
May 29, 2026
Adam Feuerstein
adam.feuerstein@statnews.com
ASCO Annual Meeting
ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
Researchers From NYU Langone Health's Perlmutter Cancer Center Present Latest Findings at 2026 ASCO Annual Meeting
Mercy BioAnalytics to Present Data at ASCO Evaluating Clinical Performance of a Blood-Based Lung Cancer Early Detection Assay in Biospecimens from the National Lung Screening Trial
Research Presented by The US Oncology Network Demonstrates How Community Practices Are Expanding Patient Access Through APP‑Led Models at ASCO 2026
Women authorship ‘still low’ in phase 3 trials at ASCO, but gains made
Science takes on the world’s most lethal malignancy
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
The ‘search for a magic bullet has faded’ in cancer immunotherapy. Here’s what’s next
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
Here's what to watch for at ASCO, cancer research's big meeting, in Chicago.
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck,…
Mystery cloaks an ASCO plenary lung cancer survival result.
It’s no secret that Akeso’s presentation will be one of the most closely watched readouts from the American Society of Clinical…
Oggi grazie a biomarcatori e analisi genomica è possibile «tagliare su misura» i trattamenti in modo impensabile rispetto al…
Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout
